Rhythm Pharmaceuticals, Inc.RYTMNASDAQ

|||

Overview News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Latest News

globenewswire.com

Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones

-- Q4 2025 preliminary net product revenues from global sales of IMCIVREE® (setmelanotide) of approximately $57 million for the fourth quarter of 2025, an 11% increase over Q3 2025 -- -- FY 2025 preliminary net product revenue of approximately $194 million, approximately 50% increase from FY2024 -- -- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity -- -- On track to report topline data from 12-patient Japanese cohort of setmelanotide Phase 3 trial in acquired hypothalamic obesity in first quarter of 2026 -- -- On track to report topline data from Phase 3 EMANATE trial evaluating setmelanotide in genetically caused MC4R pathway diseases in first quarter of 2026 -- BOSTON, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced preliminary unaudited net product revenues from global sales of IMCIVREE® (setmelanotide) for the fourth quarter and full year of 2025 and upcoming milestones. “2025 was a year of strong execution and reflects significant progress toward our mission of transforming the lives of patients with rare neuroendocrine diseases,” said David Meeker, M.D.

defenseworld.net

VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Rhythm Pharmaceuticals, Inc. $RYTM

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 6,700 shares of the company's stock, valued at approximately $677,000. Several other

defenseworld.net

Assenagon Asset Management S.A. Sells 13,870 Shares of Rhythm Pharmaceuticals, Inc. $RYTM

Assenagon Asset Management S.A. cut its holdings in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 5.8% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The firm owned 224,128 shares of the company's stock after selling 13,870 shares during the period. Assenagon Asset Management S.A. owned

defenseworld.net

Alkeon Capital Management LLC Grows Holdings in Rhythm Pharmaceuticals, Inc. $RYTM

Alkeon Capital Management LLC raised its position in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 24.5% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,017,700 shares of the company's stock after purchasing an additional 200,000 shares during the quarter.

seekingalpha.com

Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster

Rhythm Pharmaceuticals, Inc. remains a compelling rare-disease obesity platform, with a maintained Buy rating driven by progress in HO, PWS, and oral MC4R agonists. PWS Phase 2 data for IMCIVREE show early efficacy in BMI and hyperphagia reduction, though limited by small sample size and responder heterogeneity. RYTM's HO sNDA PDUFA was delayed to March 2026 for additional FDA analysis, but I remain optimistic on approval with some risk to pediatric labeling.

seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript

investors.com

Rhythm Pharma Hits Record High On Unexpected Obesity-Tied Win

Rhythm Pharmaceuticals said Thursday said it would send it would send its leading drug into registrational testing for Prader-Willi.

benzinga.com

Rhythm Pharma Strikes Chord As Early PWS Trial Results Show Promise

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) stock is higher on Thursday, after the company shared preliminary results from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS).

globenewswire.com

Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome

-- BMI and hyperphagia reductions have been observed in patients with PWS treated with setmelanotide at Month 3 (n=8) and Month 6 (n=5); 17 of 18 enrolled patients remain on therapy -- -- Promising results supportive of Phase 3, registrational trial of setmelanotide in PWS --

globenewswire.com

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Thursday, December 11 at 8:00 a.m. ET to disclose preliminary data from its exploratory Phase 2 trial of setmelanotide in patients with Prader-Willi syndrome (PWS).

seekingalpha.com

Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress

Rhythm Pharmaceuticals, Inc. maintaining a Strong Buy rating, driven by IMCIVREE's growth and multiple late-stage expansion opportunities in rare genetic obesity indications. RYTM's IMCIVREE awaits FDA label expansion for acquired hypothalamic obesity, with the PDUFA date extended to March 20, 2026, after a major filed amendment. Upcoming Q4 2025 phase 2 data for IMCIVREE in Prader-Willi Syndrome and positive Bivamelagon results for acquired hypothalamic obesity offer additional catalysts and shots on goal.

defenseworld.net

AXQ Capital LP Purchases Shares of 4,560 Rhythm Pharmaceuticals, Inc. $RYTM

AXQ Capital LP purchased a new stake in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,560 shares of the company's stock, valued at approximately $288,000. A number of other institutional investors have also made changes to

globenewswire.com

Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025

– Phase 3 TRANSCEND trial data showed setmelanotide achieved significant BMI reductions in patients with acquired hypothalamic obesity on concomitant treatment with GLP-1 therapy – – Analysis of data from Phase 3 TRANSCEND trial show clinically meaningful changes in cardiometabolic parameters in patients with acquired hypothalamic obesity treated with setmelanotide for 52 weeks – BOSTON, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that Rhythm and its partners delivered four Rhythm data presentations at ObesityWeek® 2025, held last week in Atlanta, GA. “Acquired hypothalamic obesity is a severe and complex disease that profoundly impacts the lives of patients and families, affecting not only body weight and hunger, but also causing severe implications for daily functioning,” said Christian Roth, M.D.

fool.com

Rythm Pharmaceuticals' (RYTM) Chief Technical Officer Sells 9,748 Shares for $1.1 Million

Rythm Pharmaceuticals' Chief Technical Officer, Joseph Shulman, recently exercised and sold some stock options. Shulman still held 8,509 shares directly after the trade.

globenewswire.com

Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity

-- FDA sets updated PDUFA goal date of March 20, 2026 – -- Company to hold conference today at 8:00 a.m. -- BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period for the supplemental New Drug Application (sNDA) for IMCIVREE® (setmelanotide) for the treatment of acquired hypothalamic obesity.

defenseworld.net

AlphaQuest LLC Decreases Stake in Rhythm Pharmaceuticals, Inc. $RYTM

AlphaQuest LLC lowered its stake in Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) by 77.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,470 shares of the company's stock after selling 5,137 shares during the period. AlphaQuest LLC's holdings

globenewswire.com

Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program

BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it has entered into Product Listing Agreements in the provinces of Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and with the Federal Non-Insured Health Benefits (NIHB) Program for the public reimbursement of IMCIVREE for weight management in eligible adult and pediatric patients aged 6 years and older with clinically or genetically confirmed Bardet-Biedl syndrome (BBS) and obesity. “These listing agreements for IMCIVREE mark a significant milestone for individuals living with obesity due to Bardet-Biedl syndrome,” said Prof.

seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2025 Earnings Call Transcript

Rhythm Pharmaceuticals, Inc. ( RYTM ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants David Connolly - Head of Investor Relations & Corporate Communications David Meeker - Chairman, President & CEO Jennifer Chien - Executive VP & Head of North America Yann Mazabraud - Executive VP & Head of International Hunter Smith - CFO & Treasurer Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Philip Nadeau - TD Cowen, Research Division Derek Archila - Wells Fargo Securities, LLC, Research Division Angela Qian Faisal Khurshid - Leerink Partners LLC, Research Division Erik Wong Julian Pino Evan Wang Georgia Ban Raghuram Selvaraju - H.C. Wainwright & Co, LLC, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division Presentation Operator " David Connolly Head of Investor Relations & Corporate Communications " David Meeker Chairman, President & CEO " Jennifer Chien Executive VP & Head of North America " Yann Mazabraud Executive VP & Head of International " Hunter Smith CFO & Treasurer " Michael Ulz Morgan Stanley, Research Division " Morgan Stanley, Research Division Philip Nadeau TD Cowen, Research Division " TD Cowen, Research Division Derek Archila Wells Fargo Securities, LLC, Research Division " Wells Fargo Securities, LLC, Research Division Angela Qian " Canaccord Genuity, Research Division Faisal Khurshid Leerink Partners LLC, Research Division " Leerink Partners LLC, Research Division Erik Wong " Goldman Sachs, Research Division Julian Pino " Stifel, Nicolaus & Company, Incorporated, Research Division Evan Wang " Guggenheim Securities, LLC, Research Division Georgia Ban " Jefferies LLC, Research Division Raghuram Selvaraju H.C.

zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.73 per share a year ago.

globenewswire.com

Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update

-- Third quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $51.3 million -- -- December 20, 2025 PDUFA goal date set for sNDA for setmelanotide in acquired hypothalamic obesity -- -- Company is on track to report preliminary results from setmelanotide Phase 2 trial in Prader-Willi syndrome in fourth quarter of 2025 -- -- German observational study showed setmelanotide therapy was associated with improvement in measures of MASLD and kidney function in BBS patients -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today reported financial results and provided a business update for the third quarter ended September 30, 2025.

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance